A Oklahoma overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
36.8% of Oklahoma adults have obesity, according to the CDC's BRFSS prevalence estimates for 2024 (crude prevalence) 1.
The survey year matters here more than it does in most states. Oklahoma's 2024 figure of 36.8% is notably lower than its 2023 figure of 38.7% 1 — a year-over-year decline in the published estimate, reported here as an observation about two separately labelled survey years, not as a trend we are prepared to explain. BRFSS is a telephone survey with sampling error, and we do not blend the two years into a single number or attribute the movement to any cause.
Nothing about our price is Oklahoman.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
The invoice reads the same in Guymon as it does in Norman. What changes with geography is the shipping address, not the plan.
SoonerCare, Oklahoma's Medicaid program, does not cover GLP-1 medications for obesity or weight loss. Coverage is limited to diabetes indications and requires prior authorization, so a member whose only indication is weight will not be approved for Wegovy or Zepbound on that basis.
Oklahoma sits with the large majority on this: only about ten state Medicaid programs still covered GLP-1s for obesity as of mid-2026, and KFF's tracking of state Medicaid GLP-1 policy is the clearest public record of where each program landed 3.
Commercial coverage in Oklahoma varies by employer plan rather than by state rule. Two people insured through the same carrier can get opposite answers, because weight-management drug coverage is a benefit each plan sponsor elects or declines. Check the formulary for your specific plan year rather than a carrier's general marketing page.
What to do next: search your plan-year drug list for Wegovy, Zepbound, and the phrase "weight management". If the drugs appear, ask the plan for its prior-authorization criteria in writing before your appointment. If they are excluded, or you are a SoonerCare member whose only indication is weight, the realistic routes are a documented comorbidity appeal, a manufacturer direct-pay program for the branded product, or a cash-pay physician-supervised program such as Astra's.
Yes. Oklahoma law allows a physician licensed in the state to establish a valid physician-patient relationship with a patient located in Oklahoma through telemedicine, with no prior in-person visit required for non-controlled medications such as semaglutide and tirzepatide (59 O.S. Section 478.1 5). State law defines telemedicine to include both live audiovisual visits and asynchronous store-and-forward exchanges with a health care professional, but automated text messages or automated mobile applications cannot serve as the sole interaction between you and your provider (59 O.S. Section 478 4) — every Astra visit is reviewed by a licensed provider, consistent with the standard of care. Rules for compounded medications are set at the federal level under FDA's Section 503A framework and administered by the Oklahoma State Board of Pharmacy 7, and they have changed through 2025 and 2026 after FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved 6.
Our provider group holds Oklahoma licensure and our partner pharmacies are licensed to dispense into the state, so a patient in the Panhandle or southeastern Oklahoma can be evaluated and treated at an Oklahoma address without driving to a metro specialty clinic.
Astra treats patients in Oklahoma through state-licensed physicians.
City pages carry local access context — county figures, clinician supply, and what the local market charges — under the same sourcing rules as this page.
Not for obesity. SoonerCare covers GLP-1 medications for diabetes indications only, and those require prior authorization, so weight alone is not a covered reason. As of mid-2026 only about ten state Medicaid programs still covered GLP-1s for obesity.
No, and that is deliberate. Astra charges one price in every state it serves, published once in the cost section above. There is no Oklahoma price list, no regional surcharge, and no local discount.
No. Under 59 O.S. Section 478.1, a physician licensed in Oklahoma may establish a valid physician-patient relationship with a patient located in the state through telemedicine, with no prior in-person visit required for non-controlled medications. Oklahoma's definition of telemedicine covers live audiovisual visits and asynchronous store-and-forward exchanges, but automated texts or app interactions cannot be the sole interaction between you and your provider, so a licensed provider reviews every visit.
Possibly, but only within federal 503A conditions — there are no guarantees. After FDA's transition periods ended in early-to-mid 2025, licensed pharmacies generally may no longer compound versions that are essentially copies of the FDA-approved drugs; a compounded prescription for an individual patient requires a prescriber-documented clinical reason that the FDA-approved product does not meet that patient's needs. Oklahoma's Board of Pharmacy notified its licensees of the FDA tirzepatide timeline in its February 2025 newsletter and has not adopted a separate statewide ban, so whether compounded semaglutide is an option depends on your licensed provider's clinical judgment and the dispensing pharmacy's compliance with federal and Oklahoma pharmacy law.
Tell your care team your new address before your next refill. Treatment is tied to the state you are located in when you are seen, so a provider licensed in your new state has to take over and the pharmacy has to be licensed to dispense there. If Astra serves your new state we move the plan across without restarting it; if we do not, we say so and stop billing rather than shipping into a state we are not licensed in.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.